Ethnic variations in warfarin pharmacogenetics: A comprehensive review

2025

Full text Open access: Gold Metadata (CSL-JSON)
DOI 10.7324/japs.2025.201718
Data confidence 70 medium
How this score is calculated

It is built from checkable properties of the record itself: whether the article has a DOI, how many independent sources confirmed its data, whether the required fields are filled in, and how recent the latest confirmation is. Disagreement between sources and a missing identifier lower it. A value of 80 or above means the record was published without further checking; 60 to 79 means it is published at reduced confidence, with a manual check advisable. A record verified by an editor by hand is never pushed below 90 by a recalculation. This scores our data about the article, not the article itself.

Abstract

The therapeutic dose of warfarin depends more on the patient's genotype than on the type of disease.However, to date, no uniform algorithms have been developed for warfarin dosing in different nationalities.Hence, the study aims to evaluate and structure existing recommendations for warfarin prescription in different nations.A systematic search for the necessary information for 2011-2023 on the dosage of warfarin in different ethnic groups was conducted.The databases used for this search are PubMed, Embase, Scopus, Google Scholar, and Web of Science.The correlation between various genetic polymorphisms and the pharmacodynamics and pharmacokinetics of warfarin was revealed.This primarily refers to the presence of genes of the cytochrome P450 family and vitamin K epoxide reductase complex 1.At the same time, the necessity of studying the genes CYP2C19, and gamma-glutamyl carboxylase (GGCX) is discussed.These genes can significantly improve the accuracy of existing pharmacogenetic algorithms, although they may slightly increase the individual variability of warfarin dosing.